首页> 外文期刊>Annals of Hematology >Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan
【24h】

Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan

机译:使用氟达拉滨和白消安降低强度的制备方案后成功植入了不匹配的无关脐带血移植

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We conducted a pilot study to evaluate the feasibility of reduced-intensity cord blood transplantation (RI-CBT) using a non-total body irradiation (TBI) regimen in adult patients with advanced hematologic malignancies. Seventeen patients with a median age of 58 years (range, 38–74) underwent RI-CBT at Tsukuba Memorial Hospital between April 2004 and November 2005. Preparative regimens were fludarabine 30 mg/m2 for 6 days, and busulfan 4 mg/kg for 2 days. Tacrolimus was used for prophylaxis of graft-vs-host disease (GVHD). Median numbers of infused total nucleated were 2.6×107/kg (range, 2.0–3.3). HLA disparity was found in 2/6 antigens (n=16) and 1/6 antigens (n=1). Underlying diseases progressed despite preparative regimens in four patients. Of the remaining 13 patients, nine patients achieved engraftment at a median of day 18 (range, 17–28). Six of the nine patients with engraftment achieved complete donor-type chimerism by day 100. Six patients were alive in remission at median follow-up of 13.1 months (range, 1.0–19.0). This study demonstrated the feasibility of RI-CBT using a non-TBI regimen in adults. When disease progression is controlled by the preparative regimen, RI-CBT carries a clinically significant graft-vs-tumor effect. Further studies are required to identify patients who benefit from this regimen.
机译:我们进行了一项初步研究,以评估在成人血液系统恶性肿瘤成年患者中,采用非全身照射(TBI)方案进行降低强度的脐血移植(RI-CBT)的可行性。 2004年4月至2005年11月间,在筑波纪念医院对17名中位年龄为58岁(范围38-74)的患者进行了RI-CBT治疗。准备方案为氟达拉滨30 mg / m2 6天,和白消安4毫克/公斤2天。他克莫司用于预防移植物抗宿主病(GVHD)。注入的总成核中位数为2.6×107 / kg(范围2.0–3.3)。在2/6抗原(n = 16)和1/6抗原(n = 1)中发现了HLA差异。尽管有4例患者进行了准备治疗,但基础疾病仍在进展。在其余的13例患者中,有9例在第18天的中值(17-28岁)完成了植入。到第100天时,9例植入患者中有6例完全达到了供体型嵌合。在中位随访13.1个月(范围1.0–19.0)时,有6例患者存活。这项研究证明了在成人中使用非TBI疗法进行RI-CBT的可行性。当疾病的进展由制备方案控制时,RI-CBT具有临床上显着的移植物抗肿瘤作用。需要进一步的研究来确定受益于该方案的患者。

著录项

  • 来源
    《Annals of Hematology》 |2007年第1期|49-54|共6页
  • 作者单位

    Department of Hematology Tsukuba Memorial Hospital Tsukuba Japan;

    Department of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya Japan;

    Department of Hematology Tsukuba Memorial Hospital Tsukuba Japan;

    Department of Hematology Tsukuba Memorial Hospital Tsukuba Japan;

    Department of Hematology Tsukuba Memorial Hospital Tsukuba Japan;

    Division of Exploratory Research Institute of Medical Science University of Tokyo 4-6-1 Shirokanedai Minato-ku Tokyo 108-8639 Japan;

    Department of Hematology JR Tokyo General Hospital Tokyo Japan;

    Division of Exploratory Research Institute of Medical Science University of Tokyo 4-6-1 Shirokanedai Minato-ku Tokyo 108-8639 Japan;

    Department of Hematology JR Tokyo General Hospital Tokyo Japan;

    Division of Exploratory Research Institute of Medical Science University of Tokyo 4-6-1 Shirokanedai Minato-ku Tokyo 108-8639 Japan;

    Division of Exploratory Research Institute of Medical Science University of Tokyo 4-6-1 Shirokanedai Minato-ku Tokyo 108-8639 Japan;

    Division of Exploratory Research Institute of Medical Science University of Tokyo 4-6-1 Shirokanedai Minato-ku Tokyo 108-8639 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Reduced intensity stem cell transplantation; Umbilical cord blood; Engraftment; Total body irradiation; Fludarabine; Tacrolimus;

    机译:降低强度的干细胞移植;脐带血;植入;全身照射;氟达拉滨;他克莫司;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号